We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-17.94%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$3.46B
AUM Growth
-$1.49B
Cap. Flow
-$235M
Cap. Flow %
-6.8%
Top 10 Hldgs %
72.55%
Holding
60
New
2
Increased
6
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$108M
2
GLBE icon
Global E Online
GLBE
+$16.5M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$13.9M
4
GERN icon
Geron
GERN
+$3.19M
5
RGLS
Regulus Therapeutics
RGLS
+$2.08M

Top Sells

Rank Stock Value
1
HOOD icon
Robinhood
HOOD
+$318M
2
CSPR
Casper Sleep Inc.
CSPR
+$41.6M
3
ANNX icon
Annexon
ANNX
+$10.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$6.15M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 52.93%
2 Technology 19.42%
3 Financials 18.96%
4 Industrials 5.25%
5 Communication Services 2.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKUS
26
DELISTED
Akouos Inc
AKUS
$20.4M 0.59%
4,298,488
– –
VTGN icon
27
VistaGen Therapeutics
VTGN
$12.8M
$20.2M 0.58%
543,420
– –
AFMD
28
DELISTED
Affimed
AFMD
$19.3M 0.56%
442,649
– –
TRVI icon
29
Trevi Therapeutics
TRVI
$2.64B
$17.1M 0.5%
2,798
-5,937,998
-100% -$6.15M
IVA
30
Inventiva
IVA
$1.13B
$14.9M 0.43%
1,298,700
– –
BILL icon
31
BILL Holdings
BILL
$4.78B
$14.2M 0.41%
66,100
+30
+0% +$6.25K
CVRX icon
32
CVRx
CVRX
$63.4M
$14.2M 0.41%
2,370,858
– –
OKUR
33
OnKure Therapeutics
OKUR
$168M
$14.1M 0.41%
478,692
– –
CSBR icon
34
Champions Oncology
CSBR
$72.1M
$13.9M 0.4%
1,713,720
– –
GLBE icon
35
Global E Online
GLBE
$7.11B
$13.3M 0.38%
+436,282
New +$16.5M
GNCA
36
DELISTED
Genocea Biosciences, Inc.
GNCA
$13M 0.37%
10,376,936
– –
MILE
37
DELISTED
Metromile, Inc. Common Stock
MILE
$12.4M 0.36%
9,384,285
– –
ALLK
38
DELISTED
Allakos
ALLK
$12.3M 0.36%
2,164,704
– –
STSA
39
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$11.9M 0.35%
3,142,958
– –
CBIO
40
Crescent Biopharma
CBIO
$626M
$10.4M 0.3%
90,890
– –
SYBX
41
DELISTED
Synlogic
SYBX
$10.2M 0.29%
281,961
– –
INZY
42
DELISTED
Inozyme Pharma
INZY
$10M 0.29%
2,444,379
– –
BDTX icon
43
Black Diamond Therapeutics
BDTX
$112M
$9.56M 0.28%
3,449,845
– –
PHAS
44
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$8.77M 0.25%
6,643,702
-2
-0% -$3
XERS icon
45
Xeris Biopharma Holdings
XERS
$1.45B
$8.31M 0.24%
3,246,785
-3,215
-0.1% -$7.85K
OBSV
46
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.93M 0.2%
4,586,563
– –
ELVN icon
47
Enliven Therapeutics
ELVN
$4.43B
$6.22M 0.18%
827,023
-69,570
-8% -$459K
LITS
48
Lite Strategy Inc
LITS
$30.9M
$5.14M 0.15%
426,654
– –
LXRX icon
49
Lexicon Pharmaceuticals
LXRX
$1.1B
$4.98M 0.14%
2,382,286
– –
MRKR icon
50
Marker Therapeutics
MRKR
$18.7M
$4.71M 0.14%
1,071,429
– –
1
2
3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
DF
DNCA Finance Paris, France $1.75B AUM 38.18% 1-Year Est. Return
HHAM
HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return
SFI
Siemens Fonds Invest Munich, Germany $1.75B AUM 26.24% 1-Year Est. Return
VCM
Valiant Capital Management San Francisco, California $1.74B AUM 64.05% 1-Year Est. Return

NEA Management Company's Q1 2022 Portfolio in Review

As of Q1 2022, NEA Management Company held 60 positions worth $3.46B, down 30% from $4.95B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

NEA Management Company withdrew a net $235M in Q1 2022, closing 3 positions and reducing 7 holdings. Its most notable exit was Casper Sleep Inc., an estimated $41.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 41% a quarter earlier, followed by Technology and Financials.

Against the trend, NEA Management Company opened a new position in Arcellx worth $72.2M.

  • NEA Management Company's largest Q1 2022 buy was Arcellx: 6,437,764 shares worth $72.2M.
  • NEA Management Company added most to Aurinia Pharmaceuticals in Q1 2022, an estimated $13.9M increase.
  • NEA Management Company's biggest Q1 2022 reduction was Robinhood, cutting an estimated $318M.
  • NEA Management Company fully exited Casper Sleep Inc. in Q1 2022, selling an estimated $41.6M.
  • NEA Management Company's ten largest holdings make up 73% of its $3.46B portfolio in Q1 2022.
  • NEA Management Company opened 2 new positions and closed 3 in Q1 2022.
  • NEA Management Company's portfolio value fell 30% quarter-over-quarter to $3.46B.

Based on NEA Management Company's 13F filing for Q1 2022, filed 16 May 2022.